Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk.

Fredrik Landfors Peter Henneman Elin ChorellStefan K NilssonSander Kersten

Published in: European heart journal open (2024)

Human genetic evidence suggests that therapies aimed at reducing circulating levels of ANGPTL3, ANGPTL4, and APOC3 reduce the risk of CAD. ANGPTL4 lowering may also reduce the risk of T2D.

Keyphrases

cardiovascular disease
endothelial cells
coronary artery disease
type diabetes
genome wide
emergency department
gene expression
dna methylation
induced pluripotent stem cells
copy number